These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Splicing variant of androgen receptors (AR-V7): New paradigms]. Penel N Bull Cancer; 2016 Sep; 103(9):711-3. PubMed ID: 27591905 [No Abstract] [Full Text] [Related]
4. [Management of enzalutamide, a new hormonal therapy]. Beuzeboc P; Benderra MA; de La Motte Rouge T Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670 [TBL] [Abstract][Full Text] [Related]
5. [When to begin with androgen deprivation?]. Bex A; Rübben H Urologe A; 1998 Mar; 37(2):133-4. PubMed ID: 9563119 [No Abstract] [Full Text] [Related]
6. Limiting the adverse effects of androgen suppression. Prescrire Int; 2013 Jan; 22(134):21. PubMed ID: 23367680 [TBL] [Abstract][Full Text] [Related]
7. New treatment for advanced prostate cancer. FDA Consum; 2004; 38(2):4. PubMed ID: 15101352 [No Abstract] [Full Text] [Related]
8. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
9. Prostate cancer drugs. Making sense of the options. Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308 [No Abstract] [Full Text] [Related]
10. Enzalutamide for the treatment of castration-resistant prostate cancer. Ha YS; Goodin S; DiPaola RS; Kim IY Drugs Today (Barc); 2013 Jan; 49(1):7-13. PubMed ID: 23362491 [TBL] [Abstract][Full Text] [Related]
11. Enzalutamide (Xtandi) for prostate cancer. Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121 [No Abstract] [Full Text] [Related]
12. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment]. Zgliczyński S; Borówka A Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713 [No Abstract] [Full Text] [Related]